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Short title: LCZ696 vs. Olmesartan in hypertension 
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ABSTRACT 
Effective treatment of systolic hypertension in elderly patients remains a major therapeutic 
challenge. A multicenter, double-blind, randomized controlled trial with sacubitril/valsartan 
(LCZ696), a first-in-class angiotensin-receptor-neprilysin inhibitor, was conducted to determine 
its effects versus olmesartan (angiotensin receptor blocker) on central aortic pressures, in elderly 
patients (aged ≥60 years) with systolic hypertension and pulse pressure (PP) >60 mmHg, 
indicative of arterial stiffness. Patients [N=454; mean age, 67.7 years; mean seated (ms) systolic 
BP (SBP), 158.6 mmHg; msPP, 69.7 mmHg] were randomized to receive once-daily 
sacubitril/valsartan 200 mg or olmesartan 20 mg, force-titrated to double the initial doses after 4 
weeks, prior to primary assessment at 12 weeks. The study extended double-blind treatment for 
12–52 weeks, during which amlodipine (2.5–5 mg), subsequently  hydrochlorothiazide (6.25–25 
mg) were added-on for patients not achieving BP-target (<140/90).  At Week-12, 
sacubitril/valsartan reduced central aortic systolic pressure (CASP; primary assessment) greater 
than olmesartan by −3.7 mmHg (P=0.010), further corroborated by secondary assessments at 
Week-12 (central aortic PP, −2.4 mmHg, P<0.012; mean 24-hour ambulatory brachial SBP and 
CASP, −4.1 mmHg and −3.6 mmHg, respectively, both P<0.001). Differences in 24-hour 
ambulatory pressures were pronounced during sleep. After 52 weeks, BP parameters were 
similar between treatments, however, (P<0.002) more patients required add-on antihypertensive 
therapy with olmesartan (47%), versus sacubitril/valsartan (32%) (P<0.002). Both treatments 
were equally well-tolerated. The PARAMETER study, for the first time, demonstrated 
superiority of sacubitril/valsartan versus olmesartan in reducing clinic and ambulatory central 
aortic and brachial pressures in elderly patients with systolic hypertension and stiff arteries. 
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INTRODUCTION 
Systolic hypertension and increased pulse pressure (PP) are indicative of arterial ageing and 
large artery stiffening,1, 2 which can predict incident cardiovascular (CV) disease, stroke, chronic 
kidney disease (CKD), and heart failure (HF).3-10 The correlation is even stronger with 24-hour 
ambulatory blood pressure (BP), particularly, with elevated nocturnal BP.11-15  Large artery 
stiffening with age impairs ventricular:vascular coupling by increasing characteristic impedance, 
the pressure required to generate blood flow. This explains the disproportionate rise in systolic 
pressure and PP with ageing and the increased load on the ventricle as a major risk factor for HF 
development, specifically HF with preserved ejection fraction (HFpEF).16-19  
Arterial stiffening also leads to an accelerated rise in central aortic systolic and pulse pressure 
relative to brachial pressures  leading to reduced aortic:brachial pressure pulse amplification.20  
Reducing systolic BP with antihypertensive therapies in elderly patients is associated with 
prominent reductions in morbidity and mortality due to CV disease, stroke and HF.21-24 
Emerging evidence suggest reductions in central aortic systolic pressure (CASP) and/or central 
aortic pulse pressure (CAPP) relative to brachial BP reductions could be beneficial as they are 
better indicators of left ventricular loading, systemic exposure to pressure and consequently, a 
better predictor of CV disease risk .25-27 
However, antihypertensive therapies can have differential effects on central aortic pressures, 
despite similar effects on brachial BP.28, 29 In view of the disproportionate elevation of central 
aortic pressures in patients with systolic hypertension and stiffened arteries, we were interested 
to determine whether the novel angiotensin-receptor-neprilysin inhibitor (ARNI) 
sacubitril/valsartan (LCZ696) would be more effective than conventional renin-angiotensin 
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system (RAS) blockade with an angiotensin receptor blocker (ARB), olmesartan, in reducing 
CASP and CAPP.  
Sacubitril/valsartan (LCZ696) combines the actions of an ARB, valsartan, with a neprilysin 
(NEP) inhibitor,30 sacubitril. NEP is a neutral endopeptidase that degrades a number of 
potentially beneficial vasoactive peptides, including natriuretic peptides, bradykinin, and 
adrenomedullin. Inhibition of NEP potentiates the action of these peptides and we thus 
hypothesized, that NEP inhibition simultaneous with angiotensin receptor blockade, had the 
potential to counteract some of the mechanisms contributing to arterial stiffening in patients with 
systolic hypertension and could provide more effective lowering of central aortic pressures than 
an ARB alone.  
This hypothesis was supported by two key observations that sacubitril/valsartan was more 
effective at lowering seated and ambulatory brachial BP and PP than an ARB alone,31, 32 and 
greater improvements in aortic characteristic impedance and greater reductions in aortic 
pressures in a previous study with an angiotensin converting enzyme (ACE)/NEP inhibitor 
(omapatrilat) compared with enalapril.16 Despite the clinical promise, omapatrilat was withdrawn 
due to safety concerns including increased risk of angioedema associated with the ACE-inhibitor 
component, which was seemingly potentiated by the NEP inhibition. Nevertheless, the potential 
benefit of dual RAS/NEP inhibition on aortic pressures and haemodynamics was suggested. 
More substantial support for the hypothesis came from PARADIGM-HF study, wherein 
sacubitril/valsartan showed superior clinical benefits to RAS blockade alone (enalapril) in 
reducing CV death and HF hospitalization in patients with HF and a reduced ejection fraction 
(HFrEF).33  
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The Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin 
receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study was thus 
designed to assess both the short- and long-term effects (12 and 52 weeks) of sacubitril/valsartan 
in comparison with ARB, olmesartan, on CASP and other measures of central haemodynamics 
and arterial stiffness in elderly patients with an elevated systolic BP (SBP) and an increased PP, 
indicative of increased arterial stiffness.  
 
METHODS 
Study design and patients 
The PARAMETER study design have been described in detail previously.34 In brief, the 
PARAMETER study was a multi-center, randomized, double-blind, active-controlled, parallel-
group, 52-week study conducted in 12 countries (Argentina, Colombia, France, Germany, 
Greece, Italy, Japan, Korea, Russia, Spain, Taiwan, and the USA) at 48 research sites (see online 
supplement 1 for study site details). The study comprised a screening period, a 3-4-week placebo 
run-in, and an initial double-blind monotherapy treatment period (sacubitril/valsartan versus 
olmesartan) of 12 weeks, followed by a double-blind extension of 40 weeks, during which add-
on therapy was permitted for patients not yet achieving the clinic BP treatment goal of 
<140/90mmHg. Patients were initially randomised to receive once-daily sacubitril/valsartan 200 
mg or olmesartan 20 mg for 4 weeks, followed by a forced-titration to double the initial doses for 
the remainder of the study. After 12 weeks, patients with uncontrolled BP (mean sitting [ms] 
SBP >140 mm Hg and/or ms diastolic BP [msDBP] >90 mm Hg) received open-label 
amlodipine (2.5–5 mg) followed by hydrochlorothiazide (6.25–25 mg), as needed, at an interval 
of 4 weeks up to Week 24 (on-line supplement figure S1).  
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Study participants 
The PARAMETER study recruited elderly patients (aged ≥60 years) with systolic hypertension 
(either untreated or treated with antihypertensive agents). Untreated patients (newly diagnosed or 
not treated with antihypertensive drugs for ≥4 weeks prior to screening) had an msSBP ≥150 mm 
Hg and <180 mm Hg at screening and randomization. Patients previously treated with 
antihypertensive agents prior to screening, had an msSBP ≥140 mm Hg and <180 mm Hg prior 
to 3 or 4 weeks of washout/placebo run-in and ≥150 mm Hg and <180 mm Hg at randomization. 
In addition, all patients had a PP>60 mm Hg at randomization. Patients with malignant or severe 
hypertension (msDBP ≥110 mm Hg and/or msSBP ≥ 180 mm Hg), secondary causes of 
hypertension, history of atrial fibrillation or atrial flutter d ring the 3 months prior to screening, 
or active atrial fibrillation or atrial flutter on electrocardiogram (ECG), history of CV disease 
(e.g., myocardial infarction) during 12 months prior to screening, and evidence of severe renal 
impairment (e.g., estimated glomerular filtration rate [eGFR] <30 ml/min/1.73 m2) were 
excluded.  
 
All patients provided written informed consent before starting any study-related procedure and 
the study protocol was approved by independent ethics committees or institutional review boards 
for every treatment centre and was conducted in accordance with the ethical principles of the 
Declaration of Helsinki. The study was registered as EUDract number 2012-002899-14 and 
ClinicalTrials.gov under the code NCT01692301. 
 
Efficacy assessments  
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The primary assessment of the PARAMETER study was to demonstrate the superiority of 
sacubitril/valsartan monotherapy versus olmesartan monotherapy in reducing mean CASP after 
12 weeks of treatment. Superiority testing was also pre-specified for key secondary efficacy 
outcomes, including the reduction in mean CAPP and mean ambulatory (ma) CASP and maSBP 
after 12 weeks of treatment.  
 
Additional secondary assessments tested the superiority of the sacubitril/valsartan-based regimen 
over the olmesartan-based regimen for reductions in mean CASP and CAPP from baseline to 
Week 52 endpoint and for reductions in mean aortic pulse wave velocity (PWV) from baseline to 
Week 12 and 52 endpoints. The ms central aortic diastolic BP (CADP) and mean central arterial 
pressure (CMAP), brachial pressures (msSBP, msDBP, msPP, msMAP), and 24-hour ma central 
(maCASP, maCADP, maCAPP, maCMAP) and brachial pressures (maSBP, maDBP, maPP, and 
maMAP) were also assessed at Weeks12 and 52 endpoints. Exploratory analyses include 
changes in N-terminal-pro brain natriuretic peptides (NT-proBNP) and urinary cyclic guanosine 
monophosphate (cGMP)/creatinine ratio from baseline and Week 12 and baseline and Week 52 
endpoints. 
 
Haemodynamic measurements 
Seated brachial and central aortic pressure 
Brachial BP, non-invasive central aortic pressures and carotid-femoral PWV (cf-PWV) were 
measured using the SphygmoCor XCEL System (AtCor Medical, Sydney, Australia). An 
appropriately sized brachial pressure cuff, integral to the device, was placed on the patient’s arm, 
over the brachial artery and the seated brachial SBP and DBP were recorded, and patient’s 
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brachial arterial waveform was simultaneously captured. The brachial waveform was 
automatically analyzed by the SphygmoCor brachial generalized transfer function (GTF) to 
generate a central aortic pressure waveform, and central aortic pressure indices, including CASP 
and CAPP.  
Carotid-femoral Pulse Wave Velocity 
The SphygmoCor XCEL system was also used to measure cf-PWV which is recognized as a 
clinical index of large artery stiffness.34  
Ambulatory brachial and central aortic pressures 
The 24-hour ma brachial and central aortic pressures were measured using a specialised 
oscillometric device, Mobil-O-Graph (IEM, Stolberg, Germany).35  
Plasma NT-proBNP and urinary cGMP measurements 
Biomarkers were analyzed at baseline, and Weeks 12 and 52 and expressed as change from 
baseline.  Plasma NT-proBNP was measured using the Roche Elecsys proBNP assay (Roche 
Diagnostics GmbH, Germany); urinary cGMP/creatinine ratio was measured from the first 
morning-void urine using an enzyme-linked immunosorbent assay for cGMP (R & D Systems, 
USA) and creatinine was measured using an enzymatic method.   
 
Safety assessments 
Safety and drug tolerability assessments were performed throughout the study and included 
regular monitoring and recording of all adverse events (AEs) and concomitant medications or 
significant non-drug therapies. Evaluations of routine blood chemistries, blood counts with white 
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cell differential and urine analyses, physical examinations, ECGs, and monitoring of vital signs 
were also performed at regular intervals. 
 
Sample size estimation 
A sample size of 183 patients per group, completing the first phase of the study (12 weeks) was 
estimated to be required, based on the primary assessment that is the change from baseline in 
mean CASP at 12 weeks, under the alternative hypothesis, a treatment difference of 6.5 mmHg, 
assuming a standard deviation of 19 mmHg (based on previous data).   This generated a sample 
size of 432 patients (216 per group, assuming a 15% drop-out rate) to provide 90% power to 
detect statistical significance (P<0.05, 2-sided) comparing sacubitril/valsartan treatment versus 
olmesartan in assessing the superiority at the Week 12 endpoint. 
 
Statistical analysis  
The primary assessment (change from baseline in CASP  at Week 12 endpoint), was analysed 
using a two-way analysis of covariance (ANCOVA) model with treatment and region as factors 
and the baseline as a covariate in the full analysis set (FAS), which included all patients 
randomized for the study.  Missing endpoints were imputed using last observation carried 
forward (LOCF).  
Other sec ndary assessments, excluding 24-hour ambulatory assessments, were analyzed using 
an ANCOVA model similar to the model used for the primary variable, with corresponding 
baseline assessments as a covariate. For 24-hour ambulatory assessments, a two-way repeated-
measures analysis of covariance model was used. The model included treatment, region, and 
post-dosing hours (1 through 24 hours) as factors, corresponding baseline assessment as 
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covariate, and treatment by post-dosing-hour interaction term. All analyses were conducted using 
FAS.  Multiplicity adjustment for the secondary endpoints was not considered, thus all statistical 
tests were made at a two-sided significant level of 0.05.  
The post-hoc descriptive statistics were provided for PWV and clinic SBP.  The PWV data at 12 
and 52 weeks for each quartile (using baseline PWV quartile as cut-off point) were analyzed 
using the similar ANCOVA model with treatment, region, and baseline assessment included. 
Only completers were included in the analyses and missing PWV data at Week 12 or 52 were not 
imputed. 
Mean (±standard error) changes from baseline are presented for brachial and central clinic 
pressures (msSBP, msDBP, msPP, msMAP, and CMAP) and ambulatory brachial and central 
pressures (maMAP, maCADP, maCAPP, and maCMAP) at Weeks 12 and 52. Nighttime (10pm 
to 6am) and daytime (6 am to 10pm) means for ambulatory SBP and aortic SBP were calculated. 
Mean values are presented for quartile changes in PWV, with particular focus on PWV, CASP, 
and msSBP in the upper PWV quartile at Weeks 12 and 52. Percentage reduction in geometric 
mean (95% confidence interval [CI]) is presented for biomarkers.  The last observation was 
carried forward and not imputed for missing endpoint. Safety is presented as counts and 
frequency.  SAS 9.4 was used for the analysis (SAS Institute Inc., Cary, NC). 
 
RESULTS 
Patient demographics 
A total of 454 patients were randomized to receive sacubitril/valsartan (n=229) or olmesartan 
(n=225). Of these, a total of 403 (88.8%) patients completed 12 weeks and 367 (80.8%) patients 
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completed 52 weeks, with the major reason for study discontinuation being patient/guardian 
decision followed by AEs (Figure 1). The demographics and baseline characteristics of the 
randomised patients were well balanced between the two treatment regimens (Table 1). Overall, 
52% were males and the mean age was 67.7 years, 13% patients aged ≥75 years, 64.3% White 
Caucasian, 13.5% Asian, and 8.5% Black African, 35.5% had body mass index (BMI) ≥35 
kg/m2, 99% were previously treated for hypertension with a mean duration of hypertension of 
11.9 years, and only 4 patients were hypertension-treatment-naïve, and 28.5% had type 2 
diabetes. The most common antihypertensive medications used by the patients prior to the study 
were; angiotensin receptor blockers (27.8%), ACE inhibitors (27.5%), beta blockers (11.0%), 
dihydropyridine calcium channel blockers (24.2%) and thiazides diuretics (17.6%). The other 
medications used by more than 10% of the total study population included HMG CoA reductase 
inhibitors (38.8%), biguanides (i.e. metformin) (22.0%) and acetylsalicylic acid (aspirin) 
(23.1%). 67.0%, were never smokers, 11.9% were current smokers and 21.1% were former 
smokers. The mean eGFR was 80 ml/min/1.73m2. The baseline brachial BP was 158.6/88.9 
mmHg, with a PP of 69.7 mmHg, with a corresponding baseline CASP of 144.4 mmHg and 
CAPP of 54.4 mmHg. The baseline PWV was 10.2 m/second. 
Clinic central and brachial pressures 
The mean reductions in CASP after 12 weeks of treatment from baseline, the primary 
assessment, was −12.6 mmHg (95% CI: −14, −10.1) with sacubitril/valsartan and −8.9 mmHg 
(95% CI: −11.1, −6.7) with olmesartan. The least squares mean (LSM) reductions in CASP 
(primary endpoint) were superior with sacubitril/valsartan versus olmesartan with a between-
treatment difference of −3.7 mmHg (95% CI: −6.4, −0.9 mmHg, P=0.01; Figure 2).   
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After 12 weeks of treatment the LSM reductions in CAPP (key secondary outcome) were 
superior with sacubitril/valsartan versus olmesartan with a between-treatment difference of −2.4 
mmHg (P=0.01; Figure 2). Similarly, sacubitril/valsartan lowered mean msSBP, and msPP to a 
greater extent than olmesartan at Week 12 endpoint (Table 2). In contrast, no difference was 
observed between treatments with regard to the change in CADP or msDBP from baseline to 
Week 12. 
Ambulatory central and brachial pressures 
The LSM reductions in mean 24-hour ambulatory brachial and central aortic systolic pressures 
were significantly greater with sacubitril/valsartan versus olmesartan after 12 weeks of treatment 
with a between-treatment difference of  −4.1 mmHg (P<0.001) for maSBP and −3.4 mmHg 
(P<0.001) for maCASP (Table 2). The hourly brachial and central systolic pressures over 24 
hours at Week 12 are presented in Figure 3. It is notable that the between treatment differences in 
mean 24-hour CASP and SBP are pr dominantly due to more effective reductions in both 
pressures during the nocturnal period, presumably during sleep. Nighttime (10 pm to 6 am) 
reductions in maCASP (-5.2 mmHg) and maSBP (-5.9 mmHg) were significantly (P<0.001) 
greater with sacubitril/valsartan compared with olmesartan with the greatest differences in the 
early morning hours (2 am to 6 am) in maCASP (-6.3 mmHg) and maSBP (-6.9 mmHg). 
Similarly, greater LSM reductions in maDBP, maPP, maMAP, maCADP, maCAPP and 
maCMAP (p<0.001) were observed with sacubitril/valsartan than with olmesartan at Week 12 
endpoint (Table 2). BP control rates were also greater with sacubitril/valsartan (54.0%) 
compared with olmesartan (34.7%) at Week 12 (P<0.001).  
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Add-on therapy from Week 12 to 52 
The requirement of an add-on antihypertensive therapy was significantly lower in patients treated 
with sacubitril/valsartan versus olmesartan (P<0.002) from Weeks 12 to 52. In the 
sacubitril/valsartan group, greater proportion of patients remained on monotherapy compared 
with that of the olmesartan group (68% versus 53%). Add-on amlodipine (+/− HCTZ) was 
required in 74 (32%) patients in the sacubitril/valsartan group and in 105 (47%) patients in the 
olmesartan group. 
Brachial and central aortic pressures at Week 52 
No significant differences were observed in any BP parameters (seated, ambulatory, brachial, or 
central) between the treatments at Week 52, although greater proportion of patients received add-
on antihypertensive therapy in the olmesartan group (Table 2 and Figure 2). As a result BP 
control rates were not different at the end of the study between sacubitril/valsartan (58.8%) and 
olmesartan (57.0%). 
Plasma and urinary biomarkers 
Plasma NT-proBNP was elevated at baseline (overall geometric mean was 90 pg/mL). The 
reduction in the geometric mean plasma NT-proBNP from baseline to Week 12 (online 
supplement Figure S2A) was greater in patients treated with sacubitril/valsartan (34%) compared 
with olmesartan (20%), the difference of which was attenuated by Week 52. An increase in the 
geometric mean urine cGMP/creatinine ratio from baseline to Week 12 was observed, which 
persisted at Week 52, in the sacubitril/valsartan treated patients, consistent with its mechanism of 
action. No change in urinary cGMP was observed in patients treated with olmesartan at Week 12 
or Week 52 (online supplement Figure S2B). 
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Post hoc analysis of PWV and msSBP at Weeks 12 and 52 
The LSM reductions in PWV observed with both sacubitril/valsartan and olmesartan from 
baseline at Weeks 12 and 52 were similar for each treatment (on-line supplement Figure S3A). 
The changes in PWV for each treatment stratified by quartiles of baseline PWV are shown in the 
on-line supplement Figure S4. A possible trend of greater reduction in PWV with 
sacubitril/valsartan prompted a post hoc analysis of the impact of both treatments on PWV in the 
subgroup of patients at the upper quartile of baseline PWV (mean 12.9 m/second), indicating 
stiffest arteries.  This post hoc analysis (on-line supplement Figure S3B) showed a non-
significant trend of greater LSM reductions in PWV in the sacubitril/valsartan group versus 
olmesartan group at Week 12 endpoint (between-treatment difference, −0.61 m/sec), which was 
increased by Week 52 (between-treatment difference, −0.99 m/sec).  
A post hoc analysis of SBP in the subgroup of patients in the upper quartile of PWV showed 2-
fold greater reductions in CASP and msSBP with sacubitril/valsartan versus olmesartan than that 
was observed in the overall treatment groups (Table 2), with a between-treatment difference of 
−6.0 and −7.7 mmHg and −-2.3 and −2.4 mmHg, at Weeks 12 and 52, respectively, versus −3.7 
and −3.6 mmHg and −1.5 and −1.2 mmHg in the overall treatment groups (on-line supplement 
Figure S3C-D). 
Clinic and ambulatory heart rate 
Treatment with both sacubitril/valsartan and olmesartan showed no changes from baseline mean 
sitting (~71 bpm) or ambulatory heart rate (~71 bpm) both at Week 12 and 52 endpoints. The 24-
hour ambulatory heart rate followed a similar circadian pattern as BP with no differential 
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treatment effect at daytime or nighttime and with similar reductions in heart rate during the 
nighttime period (~8 bpm). 
 
Safety assessments 
Treatments with both sacubitril/valsartan and olmesartan were generally well tolerated. The 
incidence of AEs was slightly higher in the sacubitril/valsartan-based regimen (57.6%) compared 
with the olmesartan-based regimen (53.8%), with nasopharyngitis being the most common AE.  
The overall incidence of serious AEs (SAEs) was low and similar between the 
sacubitril/valsartan (7%) and olmesartan-based regimen (5.8%; Table 3). AEs, SAEs, and drug-
related AEs leading to the study discontinuations were similar in both treatment groups.  Mild 
angioedema (mild tongue swelling) was reported in one patient in the sacubitril/valsartan group 
during Week 48, which did not require study drug interruption or hospitalization and resolved by 
the end of the study. Two deaths (one due to cardiorespiratory arrest and other due to respiratory 
failure) were reported in the olmesartan group and one death due to myocardial infarction was 
reported in the sacubitril/valsartan group. 
 
DISCUSSION   
The PARAMETER study, for the first time, shows the effect of sacubitril/valsartan on central 
aortic pressures and demonstrates the superiority of sacubitril/valsartan in lowering CASP and 
CAPP compared with conventional RAS blockade with the ARB olmesartan, after 12 weeks of 
treatment. Sacubitril/valsartan also lowered brachial SBP and PP more effectively than 
olmesartan (online supplement Figure S5), which is consistent with previously published studies 
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comparing the effect of sacubitril/valsartan with an ARB on brachial BP and PP.31, 32 This study 
also utilized new technology to measure 24-hour ambulatory central aortic pressures non-
invasively alongside conventional 24-hour ambulatory brachial BP.35 Sacubitril/valsartan was 
superior to olmesartan at lowering 24-hour ambulatory CASP and brachial SBP, with the 
differences predominantly accounted by more effective lowering of nocturnal CASP and SBP 
with sacubitril/valsartan. To our knowledge, this is the first time a drug treatment has been 
shown to be especially effective at reducing nocturnal blood pressure. This is important because 
nocturnal pressure is most strongly associated with CV risk, and CASP has been shown to 
exhibit less of a nocturnal reduction relative to brachial pressure.12, 14, 15, 36 This effect of 
sacubitril/valsartan on nocturnal pressure might have particular relevance in reducing the risk in 
people with stiffened arteries, such as elderly patients, those with diabetes and patients with 
CKD, all of whom tend to have a blunted nocturnal pressure dip.37 A characteristic of these 
patients is sodium retention and it is conceivable that the greater reduction in nocturnal BP with 
sacubitril/valsartan may be due to the diuretic action of NEP inhibition. A pharmacokinetic 
explanation is unlikely because the patients consumed their medication in the morning and the 
effect on nocturnal BP was towards the end of the dosing interval and when the patients were at 
steady state after 12 weeks treatment. 
 
The study particularly focused on elderly patients with stiffened arteries as indicated by their 
elevated brachial PP (mean at baseline ~70 mmHg) and PWV (mean at baseline 10.2 m/second) 
in addition to a high SBP relative to DBP and often isolated systolic hypertension. Such patients 
are at highest risk of CV events, stroke and HF and have disproportionate increases in their 
central aortic pressures relative to brachial pressure. Sacubitril/valsartan had a greater BP 
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lowering effect on  central and brachial SBP and PP, relative to DBP or CADP (Table 2). This is 
important for a number of reasons: (i) it mitigates against frequently quoted concerns about 
excessive lowering of DBP when treating isolated systolic hypertension, that could lead to 
compromised myocardial perfusion,2, 37; (ii) this may also be important  in treating patients with 
HFpEF who frequently have existing or antecedent systolic hypertension, stiff arteries, and a 
wide PP.17, 19 The impact of sacubitril/valsartan on clinical outcomes in patients with HFpEF is 
currently being investigated in the PARAGON-HF study 
(https://clinicaltrials.gov/ct2/show/NCT01920711); (iii) this finding also suggests an arterial ‘de-
stiffening’ effect associated with BP-lowering in patients with systolic hypertension and an 
improvement in ventricular:vascular coupling and a reduction in characteristic impedance, such 
that aortic flow is maintained at a lower aortic PP and with less left ventricular work. Prior 
studies with dual RAS/NEP inhibition with omapatrilat support this interpretation.16 A greater 
improvement in ventricular:vascular coupling with sacubitril/valsartan is supported by the 
greater reduction in NT-pro BNP (i.e. BNP release in response to cardiac wall stress) than 
olmesartan at Week 12 of the study (figure 4). Similar superior reductions in NT-pro BNP with 
sacubitril/valsartan versus RAS blockade alone (enalapril) have also been observed in the studies 
in patients with HF.38, 39  
 
We also demonstrated a significant increase in urinary cGMP levels with sacubitril/valsartan 
treatment (+45% at Week 12), which persisted throughout the study (+36% at Week 52), the 
change which was not observed with olmesartan. This increase in cGMP is consistent with the 
mechanism of action of the NEP inhibition component of sacubitril/valsartan, which decreases 
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the breakdown of potentially beneficial vasoactive peptides such as atrial natriuretic peptide, 
BNP and bradykinin, which activate guanlyate cyclase to produce cGMP.30 
 
We measured cf-PWV at baseline and Week 12 and 52, to establish whether there were 
differences in aortic stiffness with treatment and between treatments. Cf-PWV is strongly 
influenced by BP,40 and as expected cf-PWV was reduced by both treatments after 12 weeks of 
treatment and further reduced by Week 52, when the BP difference between treatment arms was 
more closely matched. We found considerably more within-patient variance than expected in cf-
PWV measurements with the technology used in this study (Sphygmocor X-CELl, AtCor, 
Australia), thereby reducing statistical power to compare the effects of sacubitril/valsartan versus 
olmesartan on aortic stiffness.  
 
Beyond the initial 12 weeks of the study, add-on antihypertensive therapy was allowed until the 
study end at 52 weeks for those patients not achieving BP target (clinic BP <140/90 mmHg). By 
Week 52, the differences in brachial and central aortic pressures between treatments had 
diminished, in large part due to the significantly greater use of add-on therapy to achieve the BP 
goal in the patients treated with olmesartan. This data reinforces the superior BP-lowering 
efficacy of sacubitril/valsartan compared with RAS blockade alone.     
 
Both treatments were similarly well tolerated throughout the 52 weeks of the study with a low 
rate of AEs (~7%) and SAEs (~2.6%), consistent with previously reported data for 
sacubitril/valsartan in patients with HFrEF.33 Moreover, unlike prior concerns of angioedema 
with dual RAS/NEP inhibition with omapatrilat (which included ACE-inhibition), excess cough 
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was not reported, and mild angioedema (mild tongue swelling) was reported in only one patient 
(African American patient from the U.S.) in the sacubitril/valsartan group during Week 48 of the 
study. No complications or hospitalisation were reported with sacubitril/valsartan in our study. 
With regard to changes in plasma potassium levels, at week 12 the change in potassium with 
LCZ696 or olmesartan was +0.1 mmol/L and +0.7 mmol/L respectively. At week 52 the change 
in potassium with LCZ696 or olmesartan was +0.3 mmol/L and +0.8 mmol/L respectively.  
More patients experienced serum potassium >5.5 mmol/L during with LCZ696 group (8.0%) 
compared with the olmesartan group (5.9%), with more severe cases (serum potassium ≥6.0 
mmol/L) in the olmesartan group (2.7%) versus the LCZ696 group (0.9%). 
 
The PARAMETER study has a number of strengths; (i) the first 12 weeks of the study allowed 
direct comparison of sacubitril/valsartan with the ARB olmesartan, uncontaminated by add-on 
therapies and showed superiority of sacubitril/valsartan with regard to central aortic and brachial 
BP reduction; (ii) BP was comprehensively evaluated with 24-hour ambulatory BP monitoring 
and 24-hour ambulatory CASP, which confirmed superior BP lowering of sacubitril/valsartan on 
both parameters and demonstrated novel BP lowering effects of sacubitril/valsartan on nocturnal 
BP; (iii) olmesartan is an ARB with a long duration of action which has previously been shown 
to reduce arterial stiffness and central aortic pressure 41, 42 and was administered at the maximal 
recommended dose to ensure an optimal comparator43; (iv) the extension of the study to 52 
weeks allowed the evaluation of effects of add-on therapies recommended by all international 
hypertension guidelines including a calcium channel blocker and/or a thiazide-type diuretic.44 
This phase of the study confirmed that less add-on therapy was required to improve BP control 
with sacubitril/valsartan versus olmesartan; and (v) finally, the study included different ethnic 
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groups and people with diabetes and no heterogeneity of effect was noted on the primary 
outcome across groups. 
The study also has some limitations; (i) the study was not designed to, and was too short to 
evaluate the effects of sacubitril/valsartan on clinical outcomes. Nevertheless, the magnitude of 
BP reduction achieved, has previously been shown to have a major beneficial impact of CV 
outcomes, stroke and HF in patients with systolic hypertension.21-23 In this regard, based on a 
recent comprehensive analysis of BP lowering on clinical outcomes,45 the magnitude of systolic 
BP fall with sacubitril/valsartan in the first 12 weeks, if maintained over the long-term, could 
result in a reduced risk of major CV disease events and coronary heart disease by ~25%, HF by 
~30%, and all-cause mortality by almost 20%; (ii) although we set out to examine the effects of 
both treatments on ameliorating aortic stiffness (cf-PWV), the methodology we used was not as 
robust as expected, and further studies, ideally using magnetic resonance imaging (MRI) are 
required to determine if sacubitril/valsartan has any specific BP-independent beneficial effects 
on ventricular:vascular coupling, aortic characteristic impedance, and distensibility. However, 
the greater reduction in NT-proBNP and pulse pressure observed with sacubitril/valsartan versus 
olmesartan indicates a ‘de-stiffening’ effect of sacubitril/valsartan and a reduction in cardiac wall 
stress. 
 
PERSPECTIVE 
The PARAMETER is the first randomized controlled trial demonstrating the ability of dual 
ARB/NEP inhibition with sacubitril/valsartan to reduce central aortic pressures (especially CASP 
and CAPP) more effectively than an ARB, in high-risk elderly patients with systolic 
hypertension and an increased PP, indicative of arterial stiffness. These results suggest that 
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sacubitril/valsartan provides beneficial effects on central aortic hemodynamics and function that 
could provide a therapeutic advantage beyond those observed with RAS blockade alone.  
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Novelty and Significance: 
What is New: This is the first randomized controlled trial comparing an Angiotensin 
Rceceptor Blocker /Neutral Endopeptidase inhibitor (ARB/NEPi) (Sacubitril/valsartan) 
versus a conventional an ARB (Olmesartan) on central aortic pressures and hemodynamics in 
elderly patients with stiff arteries and systolic hypertension. 
What is relevant: Controlling systolic hypertension is an unmet need in elderly patients and 
central aortic systolic and pulse pressures are disproportionately elevated in these patients. 
Summary: The ARB/NEPi was significantly more effective at lowering brachial and central 
aortic systolic and pulse pressures than conventional renin angiotensin system blockade with 
an ARB. 
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Legends 
 
Figure 1. Patient disposition 
*All randomized patients 
AE, adverse event 
 
Figure 2. Reduction in CASP and pulse pressure from baseline at week 12 and 52 
‡CASP was the primary efficacy   
CASP, central aortic systolic pressure; CAPP, central aortic pulse pressure 
 
Figure 3. Peripheral and central 24-hourly mean ambulatory SBP: at Week 12 (A) and Week 52 
(B) endpoints 
SBP, systolic blood pressure 
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Table 1. Demographics and baseline characteristics of the study participants 
Characteristic  
LCZ696  
regimen 
(N=229)  
Olmesartan  
regimen  
(N=225)  
P value 
Age, years 68.2 (5.73) 67.2 (5.97) 0.068 
Age group, n (%)    
>60 and <65 years 68 (29.7) 91 (40.4) 0.056 
≥65 and <75 years 129 (56.3) 107 (47.6)  
≥75 years 32 (14.0) 27 (12.0)  
Men, n (%) 119 (52.0) 118 (52.4) 0.919 
Race, n (%)    
Caucasian  148 (64.6) 144 (64.0) 1.000 
Black 20 (8.7) 19 (8.4)  
Asian 31 (13.5) 31 (13.8)  
Body mass index, kg/m2 28.6 (4.47) 29.1 (4.9†) 0.128 
Diabetes, n (%) 65 (28.4) 65 (28.9) 0.905 
Duration of hypertension, years* 11.4 (8.93) 12.3 (9.98) 0.321 
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Proportion of patients with prior 
history of hypertension (%) 
99.6 98.7 0.307 
BP and PP, mmHg    
CASP‡ 144.0 (12.65) 144.9 (12.63) 0.444 
CADP‡ 89.0 (9.58) 91.1 (10.24) 0.025 
CAPP‡  55.0 (11.86) 53.8 (12.95) 0.311 
CMAP‡  109.9 (10.25) 111.5 (9.89) 0.095 
msSBP‡  158.4 (13.41) 158.8 (13.48) 0.788 
msDBP‡ 87.8 (9.72) 89.9 (10.38) 0.027 
msPP‡  70.6 (13.00) 68.8 (14.17) 0.171 
msMAP‡  111.4 (9.24)  112.9 (9.37)  0.085 
maCASP§ 133.0 (13.63) 132.9 (12.11) 0.935 
maCADP§ 87.6 (10.14) 88.2 (9.44)  0.596 
maCAPP§ 45.3 (9.79)  44.6 (9.80)  0.523 
maCMAP§ 102.8 (10.45) 103.1 (9.33) 0.753 
maSBP|| 145.3 (14.01) 144.6 (12.83) 0.656 
maDBP|| 85.7 (10.11) 86.6 (9.42)  0.431 
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maPP|| 59.6 (11.19) 58.0 (11.29) 0.224 
maMAP|| 113.0 (10.69) 113.2 (9.59) 0.895 
PWV¶ 10.3 (2.11) 10.2 (1.91) 0.507 
msHR 70.4 (11.7) 71.2 (11.1) 0.413 
maHR 71.1 (10.2) 71.9 (9.4) 0.451 
eGFR (<60 ml/min//1.73 m2) 78.9 (19.87) 81.5 (31.91) 0.306 
Data are mean ± SD unless until specified; *n=224 for LCZ696, n=215 for olmesartan; †n=224; 
‡n=226 for LCZ696, n=220 for olmesartan; §n=159 for LCZ696, n=158 for olmesartan; ||n=164 for 
LCZ696, n=162 for olmesartan; ¶n=214 for both treatments 
BP, blood pressure; PP, pulse pressure; CASP, central aortic systolic pressure; CADP, central aortic 
diastolic pressure; CAPP, central aortic pulse pressure; CMAP, central mean arterial pressure; ms, 
mean sitting; SBP, systolic BP; DBP, diastolic BP; ma, mean ambulatory, PWV, pulse wave velocity; 
HR, heart rate; eGFR, estimated glomerular filtration rate; SD, standard deviation 
 
 
Fo
r H
yp
ert
en
sio
n P
ee
r R
ev
iew
. D
o n
ot 
dis
trib
ute
. D
es
tro
y a
fte
r u
se
.
1 
 
Table 2. Hemodynamic changes from baseline at Weeks 12 Endpoint and 52 Endpoint 
Parameter 
Change from baseline to Week 12  Change from baseline to Week 52 
LCZ696- 
regimen 
Olmesartan- 
regimen P value 
LCZ696- 
regimen 
Olmesartan- 
regimen P value 
BP and PP, mmHg       
 N=207 N=206  N=209 N=208  
CASP −12.6  
(−14.6, −10.6) 
−8.9  
(−10.9, −6.9) 0.01 
−16.2  
(−18.1, −14.3) 
−14.7  
(−16.6, −12.8) 0.271 
CADP −6.1  
(−7.4, −4.8) 
−5.0  
(−6.2, −3.7) 0.212 
−8.8  
(−10.1, −7.6) 
−8.1  
(−9.3, −6.9) 0.408 
CAPP −6.4  
(−7.7, −5.1) 
−4.0  
(−5.3, −2.6) 0.012 
−7.2  
(−8.5, −5.8) 
−6.6  
(−8.0, −5.3) 0.598 
CMAP −8.5  
(−10.0, −7.1) 
−6.5  
(−8.0, −5.0) 0.054 
−10.1 
(−11.7, −8.6) 
−8.6  
(−10.2, −7.1) 0.117 
msSBP −13.7  
(−15.9, −11.5) 
−9.9  
(−12.1, −7.6) 0.016 
−17.7  
(−19.8, −15.6) 
−16.1  
(−18.2, −14.0) 0.285 
msDBP −5.9  
(−7.1, −4.7) 
−4.9  
(−6.2, −3.7) 0.282 
−8.7  
(−9.9, −7.5) 
−8.1  
(−9.3, −6.9) 0.465 
msPP −7.7  
(−9.3, −6.2) 
−4.9  
(−6.5, −3.3) 0.013 
−8.8  
(−10.4, −7.2) 
−8.0  
(−9.6, −6.4) 0.479 
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msMAP −8.5  
(−10.0, −7.1) 
−6.6  
(−8.0, −5.1) 0.059 
−11.8  
(−13.2, −10.4) 
−10.7  
(−12.0, −9.3) 0.248 
 
N=159 N=158 
 
N=169 N=173 
 
maCASP −12.1  
(−13.2, −10.9) 
−8.7  
(−9.9, −7.5) <0.001 
−13.0  
(−14.2, −11.9) 
−13.7  
(−14.7, −12.6) 0.434 
maCADP −7.7  
(−8.4, −6.9) 
−5.7  
(−6.5, −5.0) <0.001 
−9.0  
(−9.7, −8.2) 
−8.9  
(−9.6, −8.2) 0.900 
maCAPP −4.4  
(−5.0, −3.7) 
−3.0  
(−3.6, −2.4) 0.003 
−4.0  
(−4.7, −3.3) 
−4.8  
(−5.5, −4.1) 0.078 
maCMAP −9.1  
(−10.0, −8.2) 
−6.7  
(−7.6, −5.8) <0.001 
−10.3  
(−11.2, −9.5) 
−10.5  
(−11.3, −9.7) 0.817 
 
N=164 N=162 
 
N=174 N=176 
 
maSBP −13.3  
(−14.5, −12.0) 
−9.1  
(−10.4, −7.9) <0.001 
−14.2  
(−15.3, −13.0) 
−14.3  
(−15.5, −13.2) 0.831 
maDBP −7.4  
(−8.2, −6.7) 
−5.5  
(−6.2, −4.8) <0.001 
−8.8  
(−9.5, −8.2) 
−8.4  
(−9.1, −7.8) 0.396 
maPP −5.8  
(−6.5, −5.1) 
−3.7  
(−4.4, −3.0) <0.001 
−5.3  
(−6.0, −4.6) 
−5.9  
(−6.6, −5.2) 0.193 
maMAP −10.1 
(−11.1, −9.2) 
−7.1 
(−8.0, −6.2) <0.001 
−11.3 
(−12.2, −10.4) 
−11.1 
(−12.0, −10.2) 0.737 
PWV* −0.7 
(−0.9, −0.4) 
−0.6  
(−0.8, −0.3) 0.522 
−0.8  
(−1.1, −0.6) 
−0.8  
(−1.0, −0.5) 0.731 
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Data are mean with 95% CI; *n=192 for LCZ696, n=196 for olmesartan at Week 12 endpoint; n=199 for both the treatments at Week 
52 endpoint; BP, blood pressure; PP, pulse pressure; CASP, central aortic systolic pressure; CADP, central aortic diastolic pressure; 
CAPP, central aortic pulse pressure; CMAP, central mean arterial pressure; ms, mean sitting; SBP, systolic BP; DBP, diastolic BP; 
ma, mean ambulatory; PWV, pulse wave velocity. 
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Table 3. Number of patients with adverse events (≥2% in any treatment group) in the 
double-blind period  
Variable  LCZ696-regimen 
(N=229)  
Olmesartan- regimen  
(N=225)  
Deaths 1 (0.4) 2 (0.9) 
SAEs 16 (7.0) 13 (5.8) 
Discontinuations due to AEs 16 (7.0) 14 (6.2) 
Drug-related AE discontinuations 6 (2.6) 5 (2.2) 
SAE discontinuations 6 (2.6) 6 ( 2.7) 
Any adverse event 132 (57.6) 121 (53.8) 
Any adverse event reported by ≥2%   
Nasopharyngitis 16 (7.0) 12 (5.3) 
Headache 14 (6.1) 10 (4.4) 
Dizziness 12 (5.2) 12 (5.3) 
Cough 10 (4.4) 2 (0.9) 
Influenza 7 (3.1) 5 (2.2) 
Diarrhea 6 (2.6) 5 (2.2) 
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edema peripheral 6 (2.6) 2 (0.9) 
Upper respiratory tract infection 6 (2.6) 6 (2.7) 
Abdominal pain 5 (2.2) 1 (0.4) 
Arthralgia 5 (2.2) 7 (3.1) 
Nausea 5 (2.2) 2 (0.9) 
Back pain 3 (1.3) 10 (4.4) 
Hypotension 2 (0.9) 5 (2.2) 
Data are number of patients (%).  
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